0P6S Stock Overview
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Bayer Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €28.20 |
| 52 Week High | €58.60 |
| 52 Week Low | €24.96 |
| Beta | 0.97 |
| 1 Month Change | 2.45% |
| 3 Month Change | -0.97% |
| 1 Year Change | -51.64% |
| 3 Year Change | -48.14% |
| 5 Year Change | -50.06% |
| Change since IPO | 105.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0P6S | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 2.5% | 1.5% | 0.7% |
| 1Y | -51.6% | 5.2% | 3.0% |
Return vs Industry: 0P6S underperformed the UK Pharmaceuticals industry which returned 5.2% over the past year.
Return vs Market: 0P6S underperformed the UK Market which returned 3% over the past year.
Price Volatility
| 0P6S volatility | |
|---|---|
| 0P6S Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0P6S has not had significant price volatility in the past 3 months.
Volatility Over Time: 0P6S's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1863 | 96,931 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
| 0P6S fundamental statistics | |
|---|---|
| Market cap | €27.53b |
| Earnings (TTM) | -€2.94b |
| Revenue (TTM) | €47.64b |
0.6x
P/S Ratio-9.4x
P/E RatioIs 0P6S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0P6S income statement (TTM) | |
|---|---|
| Revenue | €47.64b |
| Cost of Revenue | €19.75b |
| Gross Profit | €27.89b |
| Other Expenses | €30.83b |
| Earnings | -€2.94b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -2.99 |
| Gross Margin | 58.55% |
| Net Profit Margin | -6.17% |
| Debt/Equity Ratio | 132.3% |
How did 0P6S perform over the long term?
See historical performance and comparison